PET/CT Findings in Renal Cancer
The incidence of renal cell carcinoma (RCC) at all stages is rising, with clear cell histologic type being the commonest . However, it has been reported that 15% of small renal masses are benign . Partial or total nephrectomy is the current treatment for RCC. Contrast-enhanced computed tomography (CECT)-renal protocol  is the imaging modality of choice in detection and differentiation of solid renal masses versus cystic ones, even small ones of size <2 cm; however, it faces certain limitations consisting of its lower ability to differentiate between benign and malignant lesions, as well as indolent from aggressive phenotype [2, 3]. The role of magnetic resonance imaging (MRI) is currently mostly restricted to characterization of equivocal computed tomography (CT) findings, evaluation of perirenal fat, and venous cava thrombosis. The urge of functional characterization of renal masses has brought the utilization of PET/CT at the foreground [2, 3].
- 10.Wu HC, Yen RF, Shen YY et al (2002) Comparing whole body 18F–2-deoxyglucose positron emission tomography and technetium-99 m methylene diphosphate bone scan to detect bone metastases in patients with renal cell carcinomas: a preliminary report. J Cancer Res Clin Oncol 128(9):503–506CrossRefGoogle Scholar
- 12.Namura K, Minamimoto R, Yao M et al (2010) Impact of maximum standardized uptake value (SUVmax) evaluated by 18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) on survival for patients with advanced renal cell carcinoma: a preliminary report. BMC Cancer 10:667CrossRefGoogle Scholar
- 23.Gerety EL, Lawrence EM, Wason J et al (2015) Prospective study evaluating the relative sensitivity of 18F-NaF PET/CT for detecting skeletal metastases from renal cell carcinoma in comparison to multidetector CT and 99mTc-MDP bone scintigraphy, using an adaptive trial design. Ann Oncol 26(10):2113–2118CrossRefGoogle Scholar